ProQR Therapeutics Company Insiders
| PRQR Stock | USD 2.00 0.01 0.50% |
ProQR Therapeutics employs about 156 people. The company is managed by 17 executives with a total tenure of roughly 53 years, averaging almost 3.0 years of service per executive, having 9.18 employees per reported executive. Discussion of ProQR Therapeutics' management performance can provide insight into the enterprise performance.
| Daniel Boer CEO CEO and Member of Management Board |
| Tiffany Burt President Vice President Head - Commercial |
ProQR |
ProQR Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1406) % which means that it has lost $0.1406 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5133) %, meaning that it created substantial loss on money invested by shareholders. ProQR Therapeutics' management efficiency ratios could be used to measure how well ProQR Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/23/2024, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, ProQR Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 04/23/2024, Other Current Assets is likely to grow to about 1.6 M, while Total Current Assets are likely to drop slightly above 100.7 M.As of 04/23/2024, Common Stock Shares Outstanding is likely to drop to about 41.6 M. In addition to that, Net Loss is likely to drop to about (61.5 M)
ProQR Therapeutics Workforce Comparison
ProQR Therapeutics BV is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 5,320. ProQR Therapeutics holds roughly 156 in number of employees claiming about 2.93% of equities under Health Care industry.
ProQR Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. ProQR Therapeutics Price Series Summation is a cross summation of ProQR Therapeutics price series and its benchmark/peer.
ProQR Therapeutics Notable Stakeholders
A ProQR Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProQR Therapeutics often face trade-offs trying to please all of them. ProQR Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProQR Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel Boer | CEO and Member of Management Board | Profile | |
| Tiffany Burt | Vice President Head - Commercial | Profile | |
| Lisa Hayes | Vice President - Investor Relations and Corporate Communications | Profile | |
| Smital Shah | CFO | Profile | |
| Domenico Valerio | Founder Board | Profile | |
| Robert Cornelisse | Chief People and Organization | Profile | |
| Sarah Kiely | Vice Communications | Profile | |
| Rene Beukema | Chief Corporate Devel. Officer, General Counsel, Corporate Secretary and Member of Management Board | Profile | |
| David Rodman | Chief Development Strategy Officer | Profile | |
| Gerard Platenburg | Chief Innovation Officer | Profile | |
| Bart Klein | VP Property | Profile | |
| Noreen Henig | Chief Development Officer | Profile | |
| Aniz MD | Chief Officer | Profile | |
| Aniz Girach | Chief Medical Officer | Profile | |
| Sheila Sponselee | VP Operations | Profile | |
| Sandra Kolk | Financial Controller | Profile | |
| Jurriaan Dekkers | Chief Officer | Profile |
About ProQR Therapeutics Management Performance
The success or failure of an entity such as ProQR Therapeutics often depends on how effective the management is. ProQR Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProQR management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProQR management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.66) | (0.63) |
The data published in ProQR Therapeutics' official financial statements usually reflect ProQR Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ProQR Therapeutics. For example, before you start analyzing numbers published by ProQR accountants, it's critical to develop an understanding of what ProQR Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ProQR Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ProQR Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ProQR Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ProQR Therapeutics BV. Please utilize our Beneish M Score to check the likelihood of ProQR Therapeutics' management manipulating its earnings.
ProQR Therapeutics Workforce Analysis
Traditionally, organizations such as ProQR Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProQR Therapeutics within its industry.ProQR Therapeutics Manpower Efficiency
Return on ProQR Therapeutics Manpower
| Revenue Per Employee | 40.9K | |
| Revenue Per Executive | 375.3K | |
| Net Loss Per Employee | 176.6K | |
| Net Loss Per Executive | 1.6M | |
| Working Capital Per Employee | 556.3K | |
| Working Capital Per Executive | 5.1M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for ProQR Stock analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is ProQR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProQR Therapeutics. If investors know ProQR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProQR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.081 | Quarterly Revenue Growth 1.712 | Return On Assets (0.14) | Return On Equity (0.51) |
The market value of ProQR Therapeutics is measured differently than its book value, which is the value of ProQR that is recorded on the company's balance sheet. Investors also form their own opinion of ProQR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ProQR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProQR Therapeutics' market value can be influenced by many factors that don't directly affect ProQR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProQR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProQR Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProQR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.